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Abstract
Background: Hypercholesterolemia causes atherosclerosis in medium to large sized arteries.
Cholesterol is less known for affecting the microvasculature and has not been previously reported
to induce microvascular pathology in the central nervous system (CNS).
Results: Mice with a null mutation in the low-density lipoprotein receptor (LDLR) gene as well as
C57BL/6J mice fed a high cholesterol diet developed a distinct microvascular pathology in the CNS
that differs from cholesterol-induced atherosclerotic disease. Microvessel diameter was increased
but microvascular density and length were not consistently affected. Degenerative changes and
thickened vascular basement membranes were present ultrastructurally. The observed pathology
shares features with the microvascular pathology of Alzheimer's disease (AD), including the
presence of string-like vessels. Brain apolipoprotein E levels which have been previously found to
be elevated in LDLR-/- mice were also increased in C57BL/6J mice fed a high cholesterol diet.
Conclusion: In addition to its effects as an inducer of atherosclerosis in medium to large sized
arteries, hypercholesterolemia also induces a microvascular pathology in the CNS that shares
features of the vascular pathology found in AD. These observations suggest that high cholesterol
may induce microvascular disease in a range of CNS disorders including AD.
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Cholesterol is essential for building and maintaining cell
membranes. Many steroid hormones also require choles-
terol as a precursor. Yet, despite its role in essential bio-
chemical processes and support of membrane structure,
hypercholesterolemia is associated with negative health
outcomes especially its association with vascular disease.
In particular the level of serum low-density lipoprotein
cholesterol (LDL-C) is a key risk factor for atherosclerosis
and lowering LDL-C significantly reduces the risk of coro-
nary heart disease [1,2].
Serum cholesterol has also been suggested as a risk factor
for or modulator of neurological diseases although the
effects appear complex and disease specific. In Alzheimer's
disease (AD) much attention has focused on how choles-
terol influences the enzymes which process the amyloid
precursor protein (APP) and in particular that high cellular
cholesterol shifts APP processing towards production of the
amyloid β peptide (Aβ), which in turn accumulates in neu-
ritic plaques, while lower cellular cholesterol levels pro-
mote α-secretase cleavage of APP and prevent Aβ formation
[3]. In contrast, higher serum cholesterol levels have been
suggested to be associated with a lower risk of Parkinson's
disease [4], while low serum LDL-C levels have been asso-
ciated with worsening of amyotrophic lateral sclerosis [5].
Curiously, despite hypercholesterolemia's well-established
role in promoting ischemic heart disease, serum cholesterol
is not a strong risk factor for ischemic stroke [2,6] or vascu-
lar dementia [7].
How cholesterol modulates susceptibility to neurological
diseases is incompletely understood. Hypercholestero-
lemia is best known for producing atherosclerosis in rela-
tively large arteries such as the aorta or coronary arteries
[8]. In contrast, hypercholesterolemia is not normally
thought of as affecting microvessels pathologically even
though a substantial literature exists showing that high
cholesterol adversely affects the physiological functioning
of the microvasculature including microvessels in the
brain [9].
Here we report that mice fed a high cholesterol diet
develop a vascular pathology that affects the CNS microv-
asculature. This pathology is distinctive from cholesterol-
induced atherosclerotic disease and shares some features
of the microvascular pathology associated with AD [10].
These findings have implications for the role that choles-
terol may play in inducing vascular disease in a variety of
neurological diseases including AD.
Results
Experimental design for manipulation of plasma 
cholesterol in LDLR-/- mice
C57BL/6J mice fed a high cholesterol diet develop at most
mild elevations in plasma cholesterol. LDLR-/- mice fed a
standard low cholesterol rodent chow diet (~4-6% fat,
0.04% or less cholesterol) also have only moderately
increased plasma cholesterol levels with a slightly
increased susceptibility to atherosclerosis [11-13]. How-
ever, by increasing dietary cholesterol to 0.15% or greater
[14], plasma cholesterol in LDLR-/- mice increases dra-
matically and within 16 weeks of dietary modification the
mice develop extensive atherosclerotic lesions in the aor-
tic root [15,16].
We have previously utilized the ability to modulate
plasma cholesterol levels in LDLR-/- mice to test the
effects of relatively short term modulation of plasma cho-
lesterol (16 weeks on diet) on brain Aβ production and
behavior in LDLR-/- mice [17,18]. Hypercholesterolemia
has a well-established role in promoting atherosclerosis,
for example in the coronary arteries. Less is known about
how cholesterol affects the brain vasculature and indeed
serum cholesterol is not regarded as a major risk factor for
ischemic stroke [2,6] or vascular dementia [7]. We there-
fore determined whether short term (16 weeks) or long
term (10 months) modulation of dietary cholesterol
induces brain vascular pathology. Beginning at two
months of age, we fed C57BL/6J wild type mice and
LDLR-/- mice either low (LCD, standard laboratory chow)
or high cholesterol (HCD, 0.15% cholesterol) diets for 16
weeks or 10 months and examined the brains for vascular
pathology at the end of treatment.
Plasma cholesterol levels in C57BL6/J and LDLR-/- mice fed low- or igh-cholest rol dietsFigure 1
Plasma cholesterol levels in C57BL6/J and LDLR-/- 
mice fed low- or high-cholesterol diets. Two-month old 
C57BL/6J wild type (C57BL) or LDLR-/-mice were fed either 
low (LCD) or high (HCD) cholesterol diets for 4 or 10 
months. Plasma cholesterol was determined at baseline (Pre-
diet, n = 11/group), as well as after 4 (n = 11/group; except n 
= 12, LDLR-HCD) or 10 (n = 6, C57BL-LCD; n = 6, C57BL-
HCD; n = 5, LDLR-LCD; and n = 2, LDLR-HCD) months. 
Asterisks indicate groups different from C57BL-LCD at each 
time point (p < 0.05). Results are discussed further in the 
text.Page 2 of 11
(page number not for citation purposes)
Molecular Neurodegeneration 2009, 4:42 http://www.molecularneurodegeneration.com/content/4/1/42To verify the effects of dietary treatment, we measured
total plasma cholesterol pre- and post-treatment (Figure
1). As in our previous studies [17,18], we found that base-
line plasma cholesterol at two months of age was mod-
estly elevated in LDLR-/- mice (~160 mg/dl) compared to
C57BL/6J mice (~100 mg/dl, p = 0.0008, unpaired Stu-
dent's t test). Following 16 weeks of dietary treatment,
plasma cholesterol was ~825 mg/dl in the LDLR-/- mice
fed the HCD compared to ~280 in LDLR-/- mice contin-
ued on the LCD. Plasma cholesterol in C57BL/6J mice
ranged from 188 mg/dl in mice fed the LCD diet to 216
mg/dl in mice fed the HCD. A two-way ANOVA revealed
the expected effects of both diet (F1,41 = 12.89, p = 0.0009)
and genotype (F1,41 = 19.28, p < 0.0001) and a significant
interaction of diet and genotype (F1,41 = 10.54, p =
0.0023) with plasma cholesterol increased in LDLR-HCD
mice compared to all of the other groups (p < 0.001,
Tukey HSD). Despite 16 weeks on the HCD, plasma cho-
lesterol in C57BL/6J mice was unchanged compared to
C57BL/6J mice on the LCD.
Comparing pre- to post-16-week treatment values, a
repeated measures two-way ANOVA revealed effects of
group (F3,41 = 17.43, p < 0.0001) and time (F1,41 = 38.31,
p < 0.0001), as well as a significant interaction effect (F3,41
= 11.33, p < 0.0001) with comparisons between groups
showing that only in the LDLR-HCD group was plasma
cholesterol significantly changed from baseline (p <
0.001, Tukey HSD).
In the cohort of animals that was treated for 10 months,
plasma cholesterol was higher than 1,600 mg/dl in the
LDLR-/- mice fed the HCD compared to ~630 mg/dl in
LDLR-/- mice continued on the LCD. Two-way ANOVA
revealed effects of both diet (F1,16 = 226.7, p < 0.0001) and
genotype (F1,16 = 795.2, p < 0.0001) and a significant
interaction of diet and genotype (F1,16 = 210.1, p <
0.0001) with plasma cholesterol increased in LDLR-HCD
compared to other groups (p = 0.04 vs. C57BL-LCD and
C57BL-HCD; p = 0.06 vs. LDLR-L, unpaired t test with
Welch correction). LDLR-LCD was also increased vs. both
C57BL/6J groups (p < 0.0007). Interestingly, 10 months
on a HCD resulted in no change in cholesterol levels in
C57BL/6J mice with plasma cholesterol averaging 145
mg/dl in mice fed the LCD and 165 mg/dl in mice fed the
HCD (p = 0.4117).
Microvascular pathology in mice fed a high cholesterol 
diet
We examined the brains of six month old or one-year old
mice fed HCD or LCD diets for 4 or 10 months respec-
tively using collagen IV immunostaining to visualize the
vasculature. At both ages, microvessels in C57BL-HCD,
LDLR-LCD, and LDLR-HCD exhibited pathological
changes. Examples of pathological vessels in the hippoc-
ampus are shown in Figure 2 for mice fed these diets for
10 months. Microvessels in the C57BL-LCD mice exhib-
ited generally smooth contours and were regular in
appearance. In contrast, mice in the high cholesterol-fed
groups (C57BL-HCD and LDLR-HCD) exhibited a mix-
ture of microvessels that were often thinner and irregular
while other microvessels appeared enlarged. In addition
microvessels in C57BL-HCD and LDLR-HCD mice exhib-
Abnormal vascular morphologies in C57BL/6J and LDLR-/- mice fed a high- cholester l dietFigur  3
Abnormal vascular morphologies in C57BL/6J and 
LDLR-/- mice fed a high- cholesterol diet. Anti-collagen 
IV immunoperoxidase-stained microvessels in the hippocam-
pus of one year old C57BL/6J (A, B, C), or LDLR-/- mice (D, 
E, F) fed a HCD for 10 months. Degenerating vascular seg-
ments are indicated by arrowheads in panels A and F. Typical 
string vessels are indicated by arrows in panels D and E. Pan-
els B and C show dysmorphic and abnormally twisted ves-
sels. Scale bar = 50 μm.
Vascular pathology in C57BL/6J and LDLR-/- mice fed a high-cholesterol dietFigure 2
Vascular pathology in C57BL/6J and LDLR-/- mice fed 
a high-cholesterol diet. Anti-collagen IV immunoperoxi-
dase-stained microvessels in the hippocampus of one-year 
old C57BL/6J (A-D), or LDLR-/- mice (E-H) fed low-choles-
terol (A, B, E, F), or high-cholesterol (C, D, G, H) diets for 
10 months. Mice in the high-cholesterol fed groups (C57BL-
HCD and LDLR-HCD) exhibit a mixture of microvessels that 
are often thinner and irregular (see especially panels C, D) 
while other microvessels appear enlarged (see especially pan-
els F, H). Scale bar = 50 μm.Page 3 of 11
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like vessels while other vessels displayed a kinked or
twisted morphology (Figure 3). These changes were found
in both cortical and subcortical regions and, whereas
present in 6-month old mice fed the experimental diets
for four months, they were more apparent in one-year old
mice that had received the diets for 10 months. The thin-
ning and irregularity as well as the strings and twisted
morphologies are suggestive of a degenerative process and
are highly reminiscent of the vascular pathology seen in
AD [10,19].
To quantify the number of pathological microvessels in
the hippocampus of C57BL/6J and LDLR-/- mice fed low
or high cholesterol diets for 10 months, microvessels were
selected using a systematic-random stereologic sampling
methodology and visually classified as normal, irregular,
or abnormally dilated, tortuous, or string-like. As shown
in Figure 4, compared to C57BL-LCD mice, there were
more irregular as well as pathologic vessels in C57BL-
HCD, LDLR-LCD, and LDLR-HCD mice.
Increased microvessel diameter in mice fed a high 
cholesterol diet
To determine whether quantitative vascular parameters
were altered, we performed stereologic assessments meas-
uring vascular length, length density, and diameter on col-
lagen IV-immunostained vessels in the hippocampus of
animals fed the diets for 10 months. The most consistent
change quantitatively was that microvessel diameter was
increased in C57BL-HCD, as well as LDLR-/- fed either the
LCD or HCD. As shown in Figure 5, mean diameters
increased from 6.7 ± 0.24 μm in C57BL-LCD to 7.8 ± 0.12
μm in C57BL-HCD, 7.7 ± 0.05 μm in LDLR-LCD and 8.1
± 0.31 μm in LDLR-HCD (F1,20 = 14.00, p = 0.0013 for
diet; F1,20 = 9.319, p = 0.0063 for genotype; F1,20 = 3.554,
p = 0.074 for interaction; p < 0.015, C57BL-HCD, LDLR-
LCD and LDLR-HCD vs. C57BL-LCD, Tukey HSD; no sig-
nificant differences between C57BL-HCD, LDLR-LCD and
LDLR-HCD groups). Compared to controls where micro-
vessel length density was 1,142 ± 86 mm/mm3 (± SEM),
the length density was reduced by 21% in C57BL-HCD
(909 ± 97), by 23% in LDLR-LCD (879 ± 26) and by 15%
in LDLR-HCD (971 ± 22) with a two-way ANOVA reveal-
ing an interaction effect of diet and genotype (F1,20 =
0.9222, p = 0.34 for diet; F1,20 = 2.612, p = 0.12 for geno-
type; F1,20 = 6.435, p = 0.02 for interaction), although the
only significant group difference was that LDLR-LCD was
reduced compared to C57BL-LCD (p = 0.038, Tukey
HSD). There were no differences between the groups in
total microvessel length (p > 0.05 all group comparisons,
Tukey HSD) although a two-way ANOVA revealed an
interaction effect of diet and genotype (F1,20 = 0.1576, p =
0.6956 for diet; F1,20 = 2.461, p = 0.1324 for genotype;
F1,20 = 4.562, p = 0.0452 for interaction). Thus the most
striking change quantitatively was that hypercholestero-
Quantification of pathological microvessels in mice fed low- or high- holesterol dietsFigure 4
Quantification of pathological microvessels in mice 
fed low- or high-cholesterol diets. The number of irregu-
lar and pathological microvessels was assessed in the hippoc-
ampus of C57BL/6J and LDLR-/- mice fed low- or high-
cholesterol diets for 10 months (n = 5 per group). Microves-
sels were classified as normal, irregular, abnormally dilated, 
tortuous, or string-like. An average of 57 ± 4.6 microvessels 
were scored per animal. Abnormally dilated, tortuous and 
string vessels were summed as ''pathologic''. In panel (A), the 
average number of irregular, pathological or irregular + path-
ological microvessels per hippocampus is presented. In panel 
(B), the number of irregular + pathological vessels divided by 
the total number of vessels counted is presented. Compari-
sons were made between each experimental group and 
C57BL-LCD mice using unpaired t tests with the test of sig-
nificance according to the Holm procedure. Asterisks indi-
cate: * p = 0.01-0.05; ** p = 0.001-0.01; *** p < 0.001.
Quantification of microvascular parameters in mice fed low- or high- holesterol dietsFigure 5
Quantification of microvascular parameters in mice 
fed low- or high-cholesterol diets. Vascular parameters 
were assessed stereologically in the hippocampus of C57BL/
6J and LDLR-/- mice fed low- or high-cholesterol diets for 10 
months. Quantitative analyses were performed on collagen 
IV immunoperoxidase-stained sections (n = 6 per group). 
Data are presented as total vascular density (A), total vessel 
length per hippocampus (B), and average microvessel diame-
ter (C). Asterisks indicate values that are statistically differ-
ent from C57BL-LCD (p < 0.05, Tukey HSD).Page 4 of 11
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exhibit increased microvessel diameters.
Ultrastructural analysis of microvascular pathology
To determine the ultrastructural basis of the pathology we
examined the microvasculature by electron microscopy.
We examined animals after 16 weeks of dietary treatment,
as at that time, at the light microscopy level, microvascular
pathology was already evident. Figures 6 and 7 show
examples of microvessels in the entorhinal cortex from
each group. Microvessels in the C57BL-LCD mice exhib-
ited classic neurovascular ultrastructure with circular
lumens, intact endothelial cells and smooth capillary
walls (Figure 6A). In contrast, microvessels in C57BL-
HCD, LDLR-LCD, and LDLR-HCD groups showed vary-
ing degrees of pathology. The endothelial cell nuclear
chromatin often appeared amorphous (Figure 6B) with in
some cases the endothelial cell nuclei distorted and some-
times swollen (Figure 6C). In addition, luminal circularity
was frequently lost (Figure 6D) and there were varying
degrees of capillary wall degeneration (Figure 6E).
Figures 7A and 7B show examples of advanced degenera-
tive changes in microvessels from an LDLR-HCD mouse.
Accompanying these changes, the vascular basal laminae
(Figure 7C) were often thickened and expanded perivas-
cular spaces containing amorphous debris were some-
times apparent (Figure 7C, D). Similar changes were also
apparent in C57BL-HCD mice (Figures 6E, 7D).
ApoE protein levels in brain are increased in C57BL/6J mice 
fed a high cholesterol diet
Plasma ApoE is elevated in LDLR-/- mice and ApoE levels
rise in the presence of hypercholesterolemia [12]. We [17]
Ultrastructural analysis of the cerebral microvasculature in mice fed low- or high- cholesterol dietsFigur  6
Ultrastructural analysis of the cerebral microvascula-
ture in mice fed low- or high- cholesterol diets. Trans-
versely sectioned capillaries are shown from the entorhinal 
cortex of C57BL/6J or LDLR-/- mice fed low- (LCD) or high- 
(HCD) cholesterol diets for 4 months. The microvessel in 
panel A from a C57BL/6J mouse fed a LCD exhibits a circular 
lumen, an intact endothelial cell, and smooth capillary walls. 
Note the altered chromatin structure in the endothelial cell 
nucleus in panel B, and the swollen endothelial cell nucleus in 
panel C. A normal endothelial cell nucleus is indicated by an 
asterisk in A. Arrowheads indicate an expanded extravascu-
lar space containing amorphous debris (D), or luminal degen-
eration (E) in an LDLR-/- mouse fed a LCD (D), or a C57BL/
6J mouse fed a HCD (E). Scale bar = 1 μm.
Ultrastructural analysis of microvascular pathology in LDLR-/- and C57BL/6J miceFigure 7
Ultrastructural analysis of microvascular pathology 
in LDLR-/- and C57BL/6J mice. Additional examples of 
microvascular pathology from LDLR-HCD (A, B, E, F), LDLR-
LCD (C), and C57BL-HCD (D) are shown. In A and B, note 
the severely degenerating microvessels in an LDLR mouse 
fed a high cholesterol diet. In C, note the thickened basal 
laminae (white asterisk), expanded perivascular space (black 
asterisk), and degenerating capillary wall (arrowhead) in an 
LDLR-/- mouse fed a LCD. In D, an arrow indicates an 
expanded perivascular space filled with amorphous debris in 
a C57BL/6J mouse fed a HCD. Examples of degeneration in 
the capillary wall in LDLR-HCD mice are indicated by arrow-
heads in panels E and F. Scale bar in B = 2 μm for panels A 
and B; scale bar in D = 500 nm for panels C-F.Page 5 of 11
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vated in the brain of LDLR-/- mice. To determine whether
ApoE levels might be modulated in brain in C57BL/6J
mice fed a HCD as well, we determined by Western blot-
ting levels of ApoE in the cortex of C57BL/6J mice fed a
HCD for 16 weeks. As shown in Figure 8, compared to lab-
oratory chow-fed mice, ApoE levels were increased
approximately 5-fold in mice fed the HCD (p = 0.0002,
unpaired Student's t test). Thus brain ApoE levels are dra-
matically increased in C57BL/6J mice fed a HCD diet.
Discussion
Here we describe a novel cerebrovascular pathology asso-
ciated with feeding a high cholesterol diet to C57BL/6J
wild type or LDLR-/- mice. The pathology includes a vari-
ety of abnormal vascular morphologies including twisted
vessels and string vessels. Stereologic assessments con-
firmed a visual impression that microvessels are larger in
high cholesterol fed mice and revealed a tendency towards
a decreased vascular density in mice fed high cholesterol
diets for 10 months. At the ultrastructural level, microves-
sels showed varying degrees of endothelial cell pathology
including altered nuclear chromatin structure and nuclear
swelling as well as degenerative changes in the luminal
wall. There was also thickening of the vascular basal lam-
inae and expanded perivascular spaces often filled with
amorphous debris. All of these features are indicative of a
degenerative process and have not been previously
described as being part of the spectrum of cholesterol
related vascular pathology.
LDLR-/- mice spontaneously develop moderately
increased total plasma cholesterol levels and increased
LDL-C when fed a standard low cholesterol rodent chow
diet (~4-6% fat, 0.04% or less cholesterol). When fed a
high cholesterol diet, LDLR-/- mice develop massively
increased both total plasma cholesterol as well as LDL-C
[14]. On a standard lab chow diet, nearly all plasma cho-
lesterol in C57BL/6J mice is HDL-C [21]. However, when
fed a high cholesterol diet such as that used here, most of
the plasma cholesterol in C57BL/6J mice becomes LDL-C
and the ratio of LDL-C to HDL-C becomes inverted com-
pared to mice on a lab chow diet [22]. Thus, although we
do not have LDL-C and LDL-H levels available on the
mice in the present study, we suspect that the pathology
observed in C57BL/6J fed a high cholesterol diet likely
reflects increased LDL-C despite normal total plasma cho-
lesterol levels.
Hypercholesterolemia is best known for its role in athero-
sclerotic vascular disease, a process that is most apparent
in larger arteries such as the aorta or the coronary arteries.
Cholesterol is generally not thought to cause pathology in
the microvasculature. However, despite the lack of
reported morphological changes a substantial literature
has shown that high cholesterol/high fat diets induce
microvascular dysfunction [23-29]. In arterioles, this dys-
function takes the form of impaired responses to stimuli
that induce vasodilation, while in postcapillary venules it
is manifested as increased leukocyte and platelet adhe-
sion. For example in hypercholesterolemic LDLR-/- mice
following ischemia/reperfusion injury, larger numbers of
adherent leukocytes are seen in postcapillary venules and
vascular permeability is increased [27]. A low-grade
inflammatory response occurs in association with these
functional changes [9]. In experimental animals, func-
tional changes can be seen in the microvasculature before
arterial lesions develop and occur in multiple tissues
including the brain [9,25,26]. This report is to our knowl-
edge the first to describe pathologic changes in the micro-
vasculature associated with a high cholesterol diet.
Along with cholesterol, hypertension, and diabetes are
also potent cardiovascular risk factors for atherosclerosis
in medium to large sized arteries and both are associated
with microvascular pathology. In hypertension, the
microvascular pathology takes the form of a hyaline thick-
Expression of ApoE in brain of C57BL/6J mice fed a high-cho-lesterol dietFigu e 8
Expression of ApoE in brain of C57BL/6J mice fed a 
high-cholesterol diet. Shown are levels of ApoE deter-
mined by quantitative Western blotting on brain homoge-
nates from C57BL/6J fed a HCD (n = 5) diet for 16 weeks 
beginning at 2 months of age compared to C57BL/6J main-
tained on a LCD (n = 9). Data are shown plotted as individual 
values (A) or as summed values ± SEM (B). Asterisk indicates 
p = 0.0002 vs. control (unpaired Student's t test).Page 6 of 11
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or a hyperplastic change in which a laminated thickening
of the vessel walls occurs due to smooth muscle cell pro-
liferation as well as thickening and reduplication of the
basement membrane, a process referred to as hyperplastic
arteriosclerosis [8]. Both conditions can produce progres-
sive luminal narrowing. However, the changes described
here do not resemble either form of hypertension related
vascular pathology.
Diabetes may also be associated with hyaline arteriolo-
sclerosis [30]. However, diabetes produces its own distinc-
tive microangiopathy, one of the most consistent features
of which involves diffuse thickening of the vascular base-
ment membrane [30]. This form of microangiopathy is
seen in capillaries in a variety of tissues and is regarded as
underlying the development of diabetic nephropathy,
retinopathy, and some types of peripheral neuropathy.
The pathology described here shares some features with
diabetic microangiopathy, in terms of thickened vascular
membranes and indeed C57BL/6 mice fed a high-fat
Western diet develop hyperglycemia and insulin resist-
ance [31-33], raising the possibility that diet induced
insulin resistance might be contributing to the vascular
pathology observed here. Arguing against this possibility,
however, is the fact that C57BL/6 mice develop insulin
resistance consistently only on diets containing more than
20% fat [31-33] and do not develop insulin resistance on
lower-fat atherogenic diets [33]. C57BL/6 mice fed a 1%
cholesterol-enriched diet without increased fat (4.4%),
similar to that used here also do not become insulin resist-
ant [34]. LDLR-/- mice fed a high-fructose diet in addition
do not become insulin resistant, despite the diet elevating
plasma cholesterol levels to those as high as seen with
high-fat diets [32]. Thus, wild type C57BL/6 mice fed the
type of high-cholesterol diet used in the present study
(0.15% cholesterol/4.3% fat) do not typically develop
insulin resistance, making it unlikely that the vascular
pathology observed here can be ascribed to insulin resist-
ance.
Interestingly, some of the pathological alterations
described bear a resemblance to the vascular pathology
associated with AD. Whereas it seems that no simple cor-
relation exists between serum cholesterol levels and the
risk of developing AD [7,35,36], elevated midlife choles-
terol has been associated with an increased risk of AD [7].
In addition, higher total serum cholesterol and LDL-C cor-
relate with a more rapid cognitive decline in patients with
AD [37]. Dyslipidemia is also a component of the meta-
bolic syndrome along with obesity, hypertension, and
hyperglycemia. There has been recently much interest in
the role that the individual components of the metabolic
syndrome may play in the development of AD as well as
other dementias [38-40], with some studies suggesting
that age-related cognitive impairment is more likely to
develop when the metabolic syndrome is present [41].
AD is accompanied by vascular pathology. In the most
recognized form of this pathology, cerebral amyloid angi-
opathy, amyloid is deposited the walls of blood vessels
with leptomeningeal and neocortical arteries and arteri-
oles being most affected [42]. Vascular pathology, how-
ever, also occurs in the microvasculature leading to a
decreased density and fragmentation of microvasculature
[10,19]. Microvessels appear less branched and thin
atrophic vessels known as string vessels appear while
other vessels become kinked and looped. The cause and
relationship of vascular pathology to cognitive decline in
AD remains unclear although patients with Down syn-
drome display a similar vascular pathology that is present
in young cases devoid of neuritic plaques and neurofibril-
lary tangles [19], arguing that vascular changes may pre-
cede the development of these lesions. Alterations of the
vascular basement membranes, in particular thickening of
basement membranes, have been suggested to be an early
feature of the microvascular pathology in AD [43]. Simi-
larities between the cholesterol related pathology
described here and the microvascular pathology of AD
include the presence of string vessels, tortuous and looped
vessels, and thickened basement membranes. The pathol-
ogy observed here however differs from AD by the pres-
ence of increased microvessel diameters.
How a high-cholesterol diet induces microvascular
pathology in brain is not known. The generation of reac-
tive oxygen species, in particular superoxide is thought to
be a major factor in cholesterol's effects on dysfunction of
the microvasculature [9]. Upregulation of cell adhesion
molecules including intercellular adhesion molecule-1
(ICAM-1) and P-selectin on the endothelium along with
the release of additional cytokines from circulating lym-
phocytes likely underlie the increased leukocyte and plate-
let adhesion, and create a generally proinflammatory state
[9]. This effect is seen in experimental animals in ranges of
plasma cholesterol that are only modestly elevated.
Increased proinflammatory cytokines, microglial reac-
tion, and astrogliosis have also been seen in the brains of
LDLR-/- mice following high-cholesterol/high-fat diets
[44]. However, based on immunohistochemical staining
we have not seen any obvious microglial or astroglial reac-
tion in LDLR-/- mice fed a selective high-cholesterol diet
(unpublished observations). Clearly further studies will
be needed to delineate the molecular mechanisms under-
lying the microvascular pathology induced by a high-cho-
lesterol diet.
ApoE plays a significant role in modulating cholesterol
transport in the periphery as well as the brain where it is
known to affect for example amyloid deposition [45]. Pre-Page 7 of 11
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levels are elevated in the brain of LDLR-/- mice. Here we
show that ApoE levels in brain are also increased in
C57BL/6J mice fed a HCD. Altered ApoE levels in brain
may in addition modify responses to disease processes in
the CNS.
Conclusion
Future studies will be necessary to elucidate the exact
mechanisms that underlie the cerebral microvascular
pathology associated with elevated cholesterol. However,
collectively, these studies show that mice fed a high-cho-
lesterol diet develop a distinctive CNS microvasculature
pathology. These findings have implications for the role
that cholesterol related vascular disease might play in neu-
rological diseases including AD.
Materials and methods
Mice
Male LDLR-/- mice were purchased from Jackson Labora-
tories (Bar Harbor, MA; Ldlr KO stock # 002207 strain
name B6.12957-Ldlrtm1Her). These mice were originally
generated using a 129 ES cell line and have been back-
crossed for 10 generations onto the C57BL/6J back-
ground. Age-matched male C57BL/6J wild type mice also
obtained from Jackson Laboratories were used as controls.
Animals were housed on 12 h light/dark cycles. All proto-
cols were approved by the Mount Sinai School of Medi-
cine Institutional Animal Care and Use Committee and
were in conformance with the National Institutes of
Health "Guide for the Care and Use of Laboratory Ani-
mals".
Dietary manipulations
LDLR-/- and C57BL/6J control mice were maintained on
a standard low-cholesterol rodent chow diet containing
0.02% cholesterol and 6% fat (Lab Diet 5K52; Purina, St.
Louis, MO) until two months of age. At two months, mice
were randomly assigned to receive a low-cholesterol or
high-cholesterol diet. Those that received a high-choles-
terol diet were fed D12102N base diet (Research Diets,
New Brunswick, NJ) supplemented with 0.15% choles-
terol with a constant proportion of fat (4.3%) and other
constituents. Mice not assigned to the high-cholesterol
diet were continued on the standard low cholesterol labo-
ratory chow diet. Mice were fed their respective diets and
had access to water ad libitum for periods of 4 or 10
months.
Measurement of serum cholesterol
At the initiation of dietary manipulations and at the ter-
mination of the study, blood samples were taken from the
retro-orbital sinus and total plasma cholesterol levels were
determined using the Infinity Cholesterol Reagent kit
(Thermotrace, Arlington, TX) according to the manufac-
turer's instructions.
Tissue processing
Mice were anaesthetized with a mixture of ketamine (100
mg/kg) and xylazine (10 mg/kg) and then sacrificed by
transcardial perfusion with cold 1% paraformaldehyde in
0.1 M PBS pH 7.4 (phosphate buffered saline) for 1 min,
followed by cold 4% paraformaldehyde in 0.1 M PBS pH
7.4 for 10 min. After perfusion, brains were removed and
postfixed in 4% paraformaldehyde for 48 hrs and then
transferred to 0.1 M PBS, and stored at 4°C until section-
ing. Series of 50 μm-thick coronal sections were cut using
a Vibratome.
Histology and immunohistochemistry
Immunoperoxidase staining was performed on free-float-
ing sections using an antigen retrieval method that utilizes
a pepsin digestion treatment which has been previously
described [46]. Prior to pepsin treatment, sections were
incubated in distilled water for 5 min at 37°C and then
transferred to 1 mg/ml pepsin (Dako, Carpinteria, CA) in
0.2 N HCl. Sections were incubated in the pepsin solution
at 37°C for 10 min. After washing in PBS for 15 min at
27°C followed by three 10-min washes at room tempera-
ture, sections were processed for immunohistochemistry.
Sections were pretreated with 10% methanol/1% hydro-
gen peroxide in PBS for 10 min and then blocked with
Tris-buffered saline (TBS; 50 mM Tris-HCl, 0.15 M NaCl,
pH 7.6, 0.15 M NaCl)/0.1% Triton X-100/5% goat serum
(TBS-TGS) for 1.5 h. After a wash in PBS, sections were
incubated with rabbit polyclonal anti-collagen IV antise-
rum (1:500; Chemicon, Temecula, CA) in TBS-TGS at
room temperature overnight. Sections incubated without
primary antibody served as controls. Following a wash in
PBS, sections were incubated with goat anti-rabbit horse-
radish peroxidase (HRP)-conjugated secondary antibody
(1:500, Santa Cruz Biotechnology, Santa Cruz, CA) for 2
h in TBS-TGS. Staining was visualized using 3,3'-diami-
nobenzidine in 50 mM Tris-imidazole buffer (pH 7.6).
After being mounted on slides, sections were dried over-
night and counterstained with 0.5% cresyl violet for 6 min
followed by dehydration through a graded series of etha-
nol solutions (70, 85, 90, 100% for 2 min each). Slides
were then treated with Americlear (Fisher, Tustin, CA) for
2 min, followed by xylene for 10 min and coverslipped
with Cytoseal 60 (Richard-Allan Scientific, Kalamazoo,
MI). Sections were photographed using an Optonics
MicroFire true color microscope 1600 × 1200 digital CCD
camera (Optronics, Goleta, CA). Digital images were color
balanced using Adobe Photoshop 7.0 (Adobe Systems,
San Jose, CA).
Stereologic determination of hippocampal microvascular 
density, length, and diameter
For analysis of microvascular parameters, every 6th coro-
nal section throughout the hippocampus from LDLR-/-
and C57BL6/J mice fed high- and low-cholesterol diets for
10 months was stained with the anti-collagen IV antise-Page 8 of 11
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pus was delineated using a stereology workstation,
consisting of a modified Olympus BX50 light microscope
with a PlanApo objective 2.5× (numerical aperture [N.A.],
0.04) to delineate brain regions and a UPlanApo objective
20× (N.A., 0.8; Olympus, Tokyo, Japan). For counting, a
motorized specimen stage for automatic sampling (Ludl
Electronics; Hawthorne, NY), CCD color video camera
(HV-C20AMP; Hitachi, Tokyo, Japan), and stereology
software (StereoInvestigator; MBF Bioscience, Williston,
VT) were utilized. Vessel density and length were deter-
mined using the "Space Balls" method as previously
described [47,48]. Hemispheres with a radius of 30 μm
were placed in a systematic-random manner within the
sections. The vessel density and length was obtained from
the total number of intersections between the hemi-
spheres and vessels (at least 300-400 hits per brain half)
as described previously [48]. Vessel diameter was deter-
mined by using the "Fast Measure Line" tool of the stere-
ology software. Diameter was taken as the shortest
diameter of the outer wall of vessels coming into focus
during the Space Ball analysis. Large vessels with a diame-
ter > 30 μm were not considered as representative of the
microvasculature and were not included in the analysis
for vessel length and density. The number of irregular and
pathological microvessels was determined by randomly
selecting microvessels using the Space Balls software.
Based on visual inspection, an observer blinded to the
genotype of the animal, classified each sampled vessel as
"normal", "irregular", or abnormally "dilated", "tortu-
ous", or "string-like". Abnormally dilated, tortuous, and
string vessels were summed as "pathologic".
Electron microscopy
Electron microscopy was performed as described previ-
ously [49] using the cryofixation/cryosubstitution embed-
ding technique [50]. Three mice from each of the LDLR-/
- fed high- or low- cholesterol diets and corresponding
genotype controls (C57BL/6J) fed high- or low- choles-
terol diets for four months (n = 12 mice total) were anaes-
thetized and perfused as described above with 4%
paraformaldehyde containing 0.125% glutaraldehyde.
Tissue was removed and postfixed in the same solution
overnight. Brains were then removed and 250 μm-thick
coronal sections were cut using a Vibratome and the
entorhinal region of the cortex was dissected out. Freeze
substitution and low-temperature embedding of the spec-
imens was performed as described elsewhere [50-52]. The
slices were cryoprotected by immersion in 4% D-glucose,
followed by increasing concentrations of glycerol (from
10% to 30% in phosphate buffer, v/v). Sections were
plunged rapidly into liquid propane cooled by liquid
nitrogen (-190°C) in a Universal Cryofixation System
KF80 (Reichert-Jung, Vienna, Austria). The samples were
immersed in 0.5% uranyl acetate dissolved in anhydrous
methanol (-90°C, 24 h) in a cryosubstitution AFS unit
(Leica, Vienna, Austria). The temperature was raised from
-90°C to -45°C in steps of 4°C/h. After washing with
anhydrous methanol, the samples were infiltrated with
Lowicryl HM20 resin (Electron Microscopy Sciences, Fort
Washington, PA) at -45°C. Polymerization with ultravio-
let light (360 nm) was performed for 48 hrs at -45°C, fol-
lowed by 24 h at 0°C. Ultrathin 70 nm sections were cut
with a diamond knife on a Reichert-Jung ultramicrotome
and mounted on nickel grids using a Coat-Quick adhesive
pen (Electron Microscopy Sciences). Grids were examined
on a Joel 1200 EX electron microscope (Tokyo, Japan) and
imaged with an advantage CCD camera (Advanced Micro-
scopy Techniques, Danvers, MA). Images were adjusted
for brightness and contrast using Adobe Photoshop 7.0.
Determination of apolipoprotein E levels in brain
Mice were sacrificed with carbon dioxide and the brains
removed and regionally dissected. Apolipoprotein E (Apo
E) levels in brain were determined by quantitative West-
ern blotting with normalization to α-tubulin as previ-
ously described [17] using pooled samples of anterior and
posterior neocortex.
Statistical analysis
All data are presented as mean ± the standard error of the
mean (S.E.M.). Equality of variance was assessed using the
Levene test. Comparisons were made using two-way uni-
variate or repeated measures analysis of variance
(ANOVA) as well as unpaired t tests. When multiple com-
parisons were made for all pairs among the four groups,
the Tukey HSD procedure was used if the Levene test was
not significant (p > 0.05). Otherwise, comparisons for all
pairs of groups or selected comparisons were made using
unpaired t tests with significance determined according to
the procedure of Holm [53] to correct for multiple com-
parisons. If the Levene statistic was significant (p < 0.05)
and groups were of unequal sizes, the unpaired t tests
employed the Welch correction for unequal variances. Sta-
tistical tests were performed using the program GraphPad
Prism 4.0 (GraphPad Software, San Diego, CA) or SPSS
16.0 (SPSS, Chicago, IL).
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